NeoStem Inc has filed a patent application claiming the proprietary stem cell technology of Vincent C. Giampapa, MD, FACS, relating to cosmetic facial rejuvenation. NeoStem first licensed the technology in February 2009.
The Giampapa Institute for Anti-Aging Medical Therapy in Montclair, NJ, houses the newest adult stem cell collection center in the NeoStem network. The institute is now open, after receiving a state blood bank license for autologous peripheral blood stem cell collection. As the director of the Giampapa Institute for Anti-Aging Medical Therapy, Giampapa is a board-certified plastic reconstructive surgeon and assistant clinical professor of plastic and reconstructive surgery at the University of Medicine and Dentistry of New Jersey. He developed a non-surgical procedure for complete facial rejuvenation that involves injecting pluripotent cells, including stem cells, into the skin of individuals whose skin has lost firmness and texture due to age.
"NeoStem is very focused on acquiring technologies related to stem cell therapies," said Robin Smith, MD, NeoStem’s chief executive officer. "We are especially delighted to strengthen our relationship with Dr. Giampapa, as anti-aging technology is one of our key pursuits. Filing a patent for stem cell facial rejuvenation technology, while launching a new NeoStem collection center at the Giampapa Institute, creates a particularly advantageous situation for NeoStem.”
Smith continued that the technology represents a safer, non-invasive alternative to Botox and similar anti-wrinkle drugs, which must now carry "black box" warning labels.
[Source: Original press release]
